Christine Ann Fox Sells 9,128 Shares of Mereo BioPharma Group plc (NASDAQ:MREO) Stock

Mereo BioPharma Group plc (NASDAQ:MREO) CFO Christine Ann Fox sold 9,128 shares of the stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $4.47, for a total transaction of $40,802.16. Following the transaction, the chief financial officer now owns 108,443 shares in the company, valued at $484,740.21. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Christine Ann Fox also recently made the following trade(s):

• On Tuesday, June 25th, Christine Ann Fox sold 12,990 shares of Mereo BioPharma Group stock. The stock was sold at an average price of $3.69, for a total transaction of $47,933.10.

Mereo BioPharma Group Stock Performance

NASDAQ:MREO traded up $0.22 on Monday, hitting $4.50. 805,063 shares of the stock were exchanged, compared to its average volume of 902,555. The company’s 50-day moving average price is $4.21 and its 200 day moving average price is $3.61. Mereo BioPharma Group plc has a 52 week low of $3.64 and a 52 week high of $5.02.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on MREO. Leerink Partners boosted their price objective on Mereo BioPharma Group from $6.00 to $8.00 and gave the stock an “outperform” rating in a research report on Thursday, June 20th. Baird R W raised shares of Mereo BioPharma Group to a “strong-buy” rating in a research note on Thursday, June 13th. Cantor Fitzgerald reissued an “overweight” rating and issued a $7.00 price target on shares of Mereo BioPharma Group in a research report on Monday. Robert W. Baird began coverage on Mereo BioPharma Group in a research report on Thursday, June 13th. They set an “outperform” rating and a $8.00 price objective for the company. Finally, Needham & Company LLC restated a “buy” rating and set a $7.00 price target on shares of Mereo BioPharma Group in a research note on Tuesday, August 13th. Four analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $7.50.

Hedge Funds Weigh In On Mereo BioPharma Group

Several institutional investors have recently modified their holdings of the business. Perceptive Advisors LLC acquired a new position in shares of Mereo BioPharma Group during the 2nd quarter worth about $4,512,000. Frazier Life Sciences Management L.P. bought a new stake in shares of Mereo BioPharma Group during the 2nd quarter worth about $15,845,000. Blue Owl Capital Holdings LP acquired a new position in shares of Mereo BioPharma Group in the second quarter valued at approximately $3,232,000. Millennium Management LLC boosted its position in shares of Mereo BioPharma Group by 46.9% in the second quarter. Millennium Management LLC now owns 3,201,705 shares of the company’s stock valued at $11,526,000 after acquiring an additional 1,022,570 shares during the period. Finally, Deerfield Management Company L.P. Series C bought a new stake in Mereo BioPharma Group in the 2nd quarter valued at about $24,158,000. Institutional investors own 62.83% of the company’s stock.

About Mereo BioPharma Group

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors.